Currax Pharmaceuticals LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Currax Pharmaceuticals LLC
Wegovy and Saxenda surpass cost effectiveness thresholds at current prices, while two widely unused drugs, Qysmia and Contrave, are cost-effective at accepted benchmarks, according to a draft report from the Institute for Clinical and Economic Review.
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, research and development partnerships and commercial collaborations. This edition covers industry pacts that were signed in September and October 2019.
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Teva has seen two US patents protecting the Contrave combination of naltrexone and bupropion ruled invalid on appeal. But it is no nearer bringing a generic of the weight-loss drug to market, as the Court of appeals upheld a later-expiring patent, albeit on a split decision.
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Cypress Pharmaceutical, Inc.
- Hawthorn Pharmaceuticals, Inc.
- Nalpropion Pharmaceuticals, Inc.
- Pernix Therapeutics Holdings, Inc.
- Somaxon Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.